Simulations Plus Says Acquisition Target Has Chosen a Rival Suitor | GenomeWeb

Simulation and modeling software firm Simulations Plus said this week that an undisclosed firm it has been pursuing for six months as a potential acquisition candidate has declined its offer.

Walt Woltosz, chairman and CEO of the firm, said in a statement that the acquisition target, which would have been an addition to the pharmaceutical software and services side of its business, "is no longer under consideration."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.